Verismo Therapeutics Presents STAR-101 Clinical Trial Design at the Annual Cholangiocarcinoma Foundation Conference

SynKIR™-110 T cell therapy is designed to recognize and eliminate mesothelin-overexpressing tumors in patients with advanced cholangiocarcinoma, malignant pleural mesothelioma and ovarian cancers

Excerpt from the Press Release:

PHILADELPHIA, April 13, 2023 /PRNewswire/ — Verismo Therapeutics, a clinical-stage CAR T company, University of Penn spinout, and pioneer of the novel KIR-CAR platform technology, today announced the presentation of a poster titled, “A Phase 1 KIR-CAR Clinical Trial for Patients with Cholangiocarcinoma, Mesothelioma, or Ovarian Cancers,” at the Annual Cholangiocarcinoma Foundation Conference in Salt Lake City, Utah, April 12-14. The poster features the novel SynKIR™-110 T cell therapy, which is designed to recognize and eliminate mesothelin (MSLN)-overexpressing tumors in patients with advanced cholangiocarcinoma, malignant pleural mesothelioma and ovarian cancers.

“We are proud to be attending the Annual Cholangiocarcinoma Foundation Conference and presenting our work to the community,” said Dr. Laura Johnson, CSO of Verismo Therapeutics. “We are committed to finding new treatments for this devastating disease and we look forward to sharing our progress with the Foundation.”

The poster presents the clinical trial design for the first-in-human KIR-CAR Phase I clinical trial STAR-101. The poster discusses:

• SynKIR™-110 combines MSLN-specific antibody with NK cell signals to redirect patient T cells and eliminate MSLN-overexpressing tumors.
• Preclinical research shows prolonged CAR T cell function and superior anti-tumor responses without increased toxicity.

Click the button below to read the entire Press Release:

Continue Reading The Press Release